Financial Results : Jamjoom Pharma profit soars 53% to SAR 157M in Q1 2025

Jamjoom Pharma profit soars 53% to SAR 157M in Q1 2025

30/04/2025 Argaam Exclusive

View other reports

Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) posted a net profit of SAR 157 million in Q1 2025, a 53% increase from SAR 103 million a year earlier.



Current Quarter Comparison (M)

Compared With The
Item Q1 2024 Q1 2025 Change‬
Revenues 385.46 457.53 18.7 %
Gross Income 249.40 292.85 17.4 %
Operating Income 126.58 156.96 24.0 %
Net Income 102.97 157.03 52.5 %
Average Shares 70.00 70.00 -
Earnings Per Share before unusual items (Riyal) 1.47 2.24 52.5 %
EPS (Riyal) 1.47 2.24 52.5 %

The positive performance is driven by an 18.7% increase in revenue, supported by strong performance across key therapeutic areas – notably ophthalmology, dermatology and general medicine – and key geographies including Saudi Arabia and other GCC states in addition to Iraq.

 

Jamjoom Pharma also noted operational efficiencies achieved through an effective strategy to optimize profitability and control operating costs. Additionally, earnings were supported by a profit contribution from the joint venture in Algeria and significantly lower finance costs as compared to Q1 2024, which was weighed down by depreciation in the Egyptian pound (EGP).

 

Sequentially, net profit jumped 204.3% from SAR 51.6 million in Q4 2024.

 

Shareholders’ equity, no minority interest, stood at SAR 1.54 billion as of March 31, 2025, compared to SAR 1.46 billion a year earlier.

 

Attached Documents

 

View More Financial Results

 

Kindly, you can view the full report by subscribing to the

The report contains the details of the financial statements, The most important financial indicators, Historical information, Charts, and Forecasts of experts.

Contact Us (+966)-92000-7759

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.